NASDAQ:REGN - Regeneron Pharmaceuticals Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $365.98 +0.55 (+0.15 %) (As of 07/18/2018 04:00 PM ET)Previous Close$365.43Today's Range$360.72 - $367.2352-Week Range$281.89 - $526.12Volume456,600 shsAverage Volume907,847 shsMarket Capitalization$39.28 billionP/E Ratio27.29Dividend YieldN/ABeta1.36 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat adult patients with moderate-to-severe atopic dermatitis; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and Kevzara solution for subcutaneous injection to treat rheumatoid arthritis in adults. In addition, the company offers ARCALYST injection for cryopyrin-associated periodic syndromes; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. Further, it develops EYLEA, a trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma; and Dupixent, Praluent, Kevzara, Suptavumab, Cemiplimab, Fasinumab, Evinacumab, Nesvacumab/aflibercept, Trevogrumab, REGN1908-1909, REGN1979, REGN3470-3471-3479, REGN2477, REGN3500, REGN3767, and REGN3918, which are antibody-based clinical programs under various stages of development. The company has collaboration and license agreements with Sanofi, Bayer, Mitsubishi Tanabe Pharma, Teva, Intellia Therapeutics, Adicet Bio, Decibel Therapeutics, Astellas, Alnylam Pharmaceuticals, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Receive REGN News and Ratings via Email Sign-up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical SymbolNASDAQ:REGN CUSIP75886F10 Webwww.regeneron.com Phone914-847-7000 Debt Debt-to-Equity Ratio0.11 Current Ratio3.59 Quick Ratio2.94 Price-To-Earnings Trailing P/E Ratio27.29 Forward P/E Ratio21.28 P/E Growth1.31 Sales & Book Value Annual Sales$5.87 billion Price / Sales6.71 Cash Flow$15.9122 per share Price / Cash23.00 Book Value$57.09 per share Price / Book6.41 Profitability EPS (Most Recent Fiscal Year)$13.41 Net Income$1.20 billion Net Margins23.54% Return on Equity29.92% Return on Assets20.79% Miscellaneous Employees6,200 Outstanding Shares107,700,000Market Cap$39,282.12 Regeneron Pharmaceuticals (NASDAQ:REGN) Frequently Asked Questions What is Regeneron Pharmaceuticals' stock symbol? Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN." How were Regeneron Pharmaceuticals' earnings last quarter? Regeneron Pharmaceuticals Inc (NASDAQ:REGN) released its quarterly earnings results on Thursday, May, 3rd. The biopharmaceutical company reported $4.67 earnings per share for the quarter, missing the consensus estimate of $5.08 by $0.41. The biopharmaceutical company earned $1.51 billion during the quarter, compared to the consensus estimate of $1.50 billion. Regeneron Pharmaceuticals had a net margin of 23.54% and a return on equity of 29.92%. The business's revenue was up 14.6% on a year-over-year basis. During the same quarter last year, the firm earned $2.92 EPS. View Regeneron Pharmaceuticals' Earnings History. When is Regeneron Pharmaceuticals' next earnings date? Regeneron Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Regeneron Pharmaceuticals. What price target have analysts set for REGN? 24 brokers have issued 12 month target prices for Regeneron Pharmaceuticals' shares. Their predictions range from $290.00 to $593.00. On average, they anticipate Regeneron Pharmaceuticals' share price to reach $421.1667 in the next twelve months. This suggests a possible upside of 15.1% from the stock's current price. View Analyst Ratings for Regeneron Pharmaceuticals. What is the consensus analysts' recommendation for Regeneron Pharmaceuticals? 24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 13 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Hold." What are Wall Street analysts saying about Regeneron Pharmaceuticals stock? Here are some recent quotes from research analysts about Regeneron Pharmaceuticals stock: 1. According to Zacks Investment Research, "The performance of Regeneron's key growth driver, Eylea, is impressive and the potential label expansion of Eylea in patients with wet age-related macular degeneration will further boost sales. Meanwhile, Dupixent uptake in the United States for moderate-to-severe atopic dermatitis was encouraging and a label expansion of the drug will further boost sales. However, the company is heavily dependent on Eylea for growth. Investors are cautious as the company had earlier suffered setback when it decided not to advance the nesvacumab and Eylea combination study to phase III development after two phase II studies evaluating the combination therapy failed to show additional benefit over Eylea monotherapy in patients with diabetic macular edema or wet age-related macular degeneration. Any setbacks will adversely hurt the stock. Shares have underperofrmed the industry in the last six months." (7/3/2018) 2. Canaccord Genuity analysts commented, "We are encouraged by better US Dupixent growth, but recognize that the pediatric atopic dermatitis market will be the core growth driver, with approval expected around 2021. Also, while we understand that REGN and investors are focusing more on Dupixent’s growth than EYLEA’s, the lack of EYLEA guidance going forward is concerning. REGN cannot give guidance on Dupixent since Sanofi books the revenues, and EYLEA is still expected to be the core revenue driver for REGN." (2/7/2018) Who are some of Regeneron Pharmaceuticals' key competitors? Some companies that are related to Regeneron Pharmaceuticals include AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN), Shire (SHPG), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS) and Takeda Pharmaceutical (TKPYY). Who are Regeneron Pharmaceuticals' key executives? Regeneron Pharmaceuticals' management team includes the folowing people: Dr. Leonard S. Schleifer, Co-Founder, Pres, CEO & Exec. Director (Age 65)Dr. George D. Yancopoulos, Pres, Chief Scientific Officer & Director (Age 58)Mr. Robert E. Landry Jr., Sr. VP of Fin. & CFO (Age 54)Dr. Neil Stahl, Exec. VP of R&D (Age 61)Mr. Daniel P. Van Plew, Exec. VP and Gen. Mang. of Industrial Operations & Product Supply (Age 45) Has Regeneron Pharmaceuticals been receiving favorable news coverage? Press coverage about REGN stock has been trending somewhat positive on Wednesday, Accern reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Regeneron Pharmaceuticals earned a coverage optimism score of 0.03 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 46.61 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term. Who are Regeneron Pharmaceuticals' major shareholders? Regeneron Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include SANOFI (95.60%), Manning & Napier Group LLC (0.48%), Assenagon Asset Management S.A. (0.11%), Bank of Montreal Can (0.04%), Retirement Systems of Alabama (0.03%) and Gulf International Bank UK Ltd (0.02%). Company insiders that own Regeneron Pharmaceuticals stock include Arthur F Ryan, Charles A Baker, George L Sing, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry, Robert J Terifay and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals. Which institutional investors are selling Regeneron Pharmaceuticals stock? REGN stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Westpac Banking Corp, Boston Advisors LLC, Calamos Advisors LLC, Gateway Investment Advisers LLC, Retirement Systems of Alabama, Xact Kapitalforvaltning AB and Investment House LLC. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Charles A Baker, George L Sing, Joseph L Goldstein, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry and Sanofi. View Insider Buying and Selling for Regeneron Pharmaceuticals. Which institutional investors are buying Regeneron Pharmaceuticals stock? REGN stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Manning & Napier Group LLC, Financial & Investment Management Group Ltd., Essex Investment Management Co. LLC, State of Alaska Department of Revenue, IFM Investors Pty Ltd, Cito Capital Group LLC and Gulf International Bank UK Ltd. View Insider Buying and Selling for Regeneron Pharmaceuticals. How do I buy shares of Regeneron Pharmaceuticals? Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Regeneron Pharmaceuticals' stock price today? One share of REGN stock can currently be purchased for approximately $365.98. How big of a company is Regeneron Pharmaceuticals? Regeneron Pharmaceuticals has a market capitalization of $39.28 billion and generates $5.87 billion in revenue each year. The biopharmaceutical company earns $1.20 billion in net income (profit) each year or $13.41 on an earnings per share basis. Regeneron Pharmaceuticals employs 6,200 workers across the globe. How can I contact Regeneron Pharmaceuticals? Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected] MarketBeat Community Rating for Regeneron Pharmaceuticals (NASDAQ REGN)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 1,090 (Vote Outperform)Underperform Votes: 886 (Vote Underperform)Total Votes: 1,976MarketBeat's community ratings are surveys of what our community members think about Regeneron Pharmaceuticals and other stocks. Vote "Outperform" if you believe REGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REGN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/18/2018 by MarketBeat.com StaffFeatured Article: What are Closed-End Mutual Funds?